Arkolith/Insider Trading/AMLX/Form 4

Klee Justin B.

Co-Chief Executive Officer, DirectorAmylyx Pharmaceuticals, Inc. (AMLX) · full profile →Form 4 · filed Jan 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.9M
Net Open-Market Flow
-$1.9M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 16, 2026Option exercise(M)3K$7.57$22K3.4M
Jan 16, 2026Sell(S)2K$13.89$28K3.4M
Jan 15, 2026Option exercise(M)197K$7.57$1.5M3.5M
Jan 15, 2026Sell(S)136K$13.58$1.8M3.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 16, 2026Option exercise(M)3K—$00
Jan 15, 2026Option exercise(M)197K—$03K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-017056) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Amylyx Pharmaceuticals, Inc.

Build

Ask your agent about AMLX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-017056"
Ask your agent
Use Arkolith to summarize insider buying and selling at Amylyx Pharmaceuticals, Inc.
over the last 90 days and cite the filings.